Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000159459
Ethics application status
Approved
Date submitted
13/12/2024
Date registered
11/02/2025
Date last updated
6/04/2025
Date data sharing statement initially provided
11/02/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction
Query!
Scientific title
Evaluating the Safety of the XPD System for Periosteal Distraction in patients with non-healing diabetic foot ulcers
Query!
Secondary ID [1]
313567
0
BD-PD-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetic Foot Ulcers
336078
0
Query!
Condition category
Condition code
Metabolic and Endocrine
332633
332633
0
0
Query!
Diabetes
Query!
Skin
332632
332632
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The BioDynamik XPD System is intended to be used for increased perfusion of the lower extremities to promote healing of ulcers. The XPD System involves inserting a Distraction Plate under the periosteum surgically, performed by an orthopaedic surgeon. This will take approximately 30 minutes. Following a latency period of three days to allow for healing and tissue adaptation, daily distractions are performed in regular intervals to apply slow and gradual tension on the periosteum. A distraction involves using a provided hex key, to turn the matching screw in the distraction plate. The periosteal distraction rate is 0.5mm per day, performed in two sessions. Each session involves rotating the actuation screw a half-turn, delivering a precise 0.25mm of movement. The distraction process continues for 20 days until a total of 10mm distraction is achieved. Patients will be performing their own distraction, and are provided with instructional text and a distraction log to ensure compliance.
At the end of the distraction phase, a second latency period of two days is observed before returning the device back to the starting position. The retraction procedure is performed by retracting the plate 5mm per day, performed in two 2.5mm retraction sessions per day. Returning the plate to the starting position marks the completion of the periosteal distraction therapy, after which the device is removed surgically from the patient by an orthopaedic surgeon.
Following removal of the device, the patient will be observed for an additional 16 weeks to assess safety monitoring, would healing, patient health, and growth factors. The total study duration is 21 weeks (1 week screening, 4 weeks with device inserted, 16-week follow-up).
Query!
Intervention code [1]
330159
0
Treatment: Devices
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
340141
0
Percentage of change in area of ulcers
Query!
Assessment method [1]
340141
0
Digital Planimetry
Query!
Timepoint [1]
340141
0
12, 16 and 20 weeks post-treatment using the XPD system compared to baseline measurements.
Query!
Primary outcome [2]
340140
0
The primary safety endpoint for this study is a composite outcome of the incidence and severity of adverse events (AEs).
Query!
Assessment method [2]
340140
0
Monitoring and recording of adverse events. This will be a combination of participant reported, and observed by clinician. Possible related adverse events include; infection of the skin, loosening of the device where it is attached to the leg, osteomyelitis (infection of the bone), skin necrosis, fracture tibia. Appropriate medical tools and tests will be used specific to the event (e.g. X-ray for bone fracture).
Query!
Timepoint [2]
340140
0
Occurence of adverse events will be reviewed weekly post-treatment using the XPD system, for the first 12 weeks. Then at weeks 16 and 20 post-treatment using the XPD system.
Query!
Secondary outcome [1]
442954
0
Percentage of patients with complete wound healing
Query!
Assessment method [1]
442954
0
Ulcer Assessment
Query!
Timepoint [1]
442954
0
12, 16 and 20 weeks post-treatment using the XPD system
Query!
Secondary outcome [2]
442957
0
Changes in systemic serum level growth factors (vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF)). This will be assessed as a composite outcome.
Query!
Assessment method [2]
442957
0
Serum growth factors assays
Query!
Timepoint [2]
442957
0
Week 4, week 6, week 8 and week 14 post-treatment using the XPD system
Query!
Secondary outcome [3]
442955
0
Peripheral limb perfusion
Query!
Assessment method [3]
442955
0
Vascular Perfusion Assessment
Query!
Timepoint [3]
442955
0
4 weeks, 6 weeks, 8 weeks, 14 weeks, 16 weeks and 20 weeks post-treatment using the XPD system
Query!
Secondary outcome [4]
442958
0
Peripheral neuropathy
Query!
Assessment method [4]
442958
0
Semmes-Weinstein monofilament (SWM) test score
Query!
Timepoint [4]
442958
0
Week 8, week 14 and week 16, and 20 post-treatment using the XPD system
Query!
Secondary outcome [5]
442960
0
Number of patients with amputation resulting from index wound
Query!
Assessment method [5]
442960
0
Investigators will confirm amputation status at follow-up visits, and document it accordingly in source records (e.g. eMR).
Query!
Timepoint [5]
442960
0
Investigators will confirm amputation status weekly post-treatment using the XPD system, for the first 12 weeks. Then at weeks 16 and 20 post-treatment using the XPD system.
Query!
Secondary outcome [6]
442956
0
Time to greater than or equal to 50% area reduction wound closure
Query!
Assessment method [6]
442956
0
Digital Planimetry
Query!
Timepoint [6]
442956
0
Assessed at 8-weeks, 12-weeks, 16-weeks, and 20-weeks post-treatment using the XPD system.
Query!
Secondary outcome [7]
442959
0
Change in ulcer reported pain
Query!
Assessment method [7]
442959
0
Visual Analogue Scale (VAS) and Wound Quality of Life (WQoL) . This will be assessed as a composite outcome.
Query!
Timepoint [7]
442959
0
Week 4, week 6, week 8 and week 14, week 16, and week 20, post-treatment using the XPD system
Query!
Eligibility
Key inclusion criteria
1. Male or female greater than or equal to 18 years
2. Participant is willing and able to sign informed consent
3. Current reference ulcer has been present for greater than 30 days prior to enrolment
4.Using the 'Wound, Ischemia, and Foot Infection' (WIfI) criteria the patient has (W)1-2, (I)1-3, (fI)0-1
5. Patients with a diagnosis of diabetes must have a HbA1c of less than or equal to 12% at screening and considered stable and controlled with no changes in diabetic medication regimen anticipated during the study period
6. Patients with mild/moderate foot ischemia, confirmed at baseline (Day 0) based upon the following criteria for the affected foot: a) Toe Pressure (TP) less than 50 mmHg or b) Ankle Systolic Pressure (ASP) less than or equal to 70 mmHg or c) TcPO2 less than 40 mmHg
7. Participants or responsible caregiver must be willing to undergo protocol-defined standardized wound care and all study procedures during the study period
8. Ulcer is either located on the foot or ankle with at least 50% of ulcer below medial aspect of the malleolus
9. Ulcer size (area) greater than or equal to 1cm2 and less than or equal to 25cm2 at screening visit
a) If heel ulcer, area less than 4cm2
10. Females of childbearing potential* must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence) during the course of the study and undergo pregnancy tests (serum or urine) as required
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participant was previously enrolled and treated under this clinical study protocol
2. Participant has WIfI (W)3 or (fI)2-3
3. Participant has a history of hypersensitivity to nickel, as determined by prior medical history
4. Participant has participated in another clinical trial involving a device or a systemically administered investigational study drug/treatment within 30 days of enrolment.
5. Participant has a history of bone cancer or metastatic disease on the index limb, radiation therapy to the foot, or has had chemotherapy within twelve (12) months (365 days) prior to signing informed consent form for trial participation
6. Reference ulcer, in the clinical opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
7. Participants with end-stage renal disease receiving dialysis treatment.
8. In the clinical opinion of the Investigator, the participant has an active or unstable Charcot foot
9. Participant has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes within 30 days of enrolment or is scheduled to receive treatment during the study
10. Participant has been treated with Negative Pressure Wound Therapy (NPWT, hyperbaric oxygen or topical oxygen therapy within thirty (30) days of the Screening Visit or is scheduled to receive such treatments during the study
11. Participant with a history of more than two (2) weeks treatment with immunosuppressants including prednisone 10 mg daily or an equivalent dose of other oral steroids, or application of topical steroids to the ulcer surface within one (1) month (30 days) prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
12. Participant is not considered a good candidate for this clinical trial in the opinion of the investigator.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
The general analytical approach for all endpoints will be descriptive in nature. Descriptive statistics for continuous variables will include the number of observations available (n), mean, standard deviation, medians, and interquartile ranges (IQR) as needed, and minimum value, and maximum value. Descriptive statistics for categorical variables will include frequency counts and percentages per category. All missing values will generally not be imputed. All significance tests will be conducted at the level of 0.05 (two-sided) without further multiplicity adjustment in this early-stage feasibility study.
No formal sample size calculation has been performed, and the sample size is empirical. As this is a FIH feasibility study, a sample size of 20 participants is considered sufficient to adequately characterise the general safety profile and preliminary efficacy evidence of XPD System.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
2/06/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/12/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
30/04/2026
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,WA
Query!
Funding & Sponsors
Funding source category [1]
318030
0
Commercial sector/Industry
Query!
Name [1]
318030
0
BioDynamik Inc.
Query!
Address [1]
318030
0
Query!
Country [1]
318030
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
BioDynamik Inc.
Query!
Address
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
320376
0
None
Query!
Name [1]
320376
0
Query!
Address [1]
320376
0
Query!
Country [1]
320376
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316687
0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Query!
Ethics committee address [1]
316687
0
https://svhm.org.au/home/research/researchers/human-research-ethics-committee
Query!
Ethics committee country [1]
316687
0
Australia
Query!
Date submitted for ethics approval [1]
316687
0
17/12/2024
Query!
Approval date [1]
316687
0
31/03/2025
Query!
Ethics approval number [1]
316687
0
HREC-313/24
Query!
Summary
Brief summary
Chronic, non-healing foot and leg ulcers are often a result of reduced blood flow due to Peripheral Artery Disease (PAD) or other ischemic (reduced blood flow) conditions in patients with chronic diseases, including diabetes. These ulcers can compromise quality of life and increase the risk of serious infection and tissues necrosis (injury and death of the tissue). Periosteal distraction (PD) is a medical technique used to increased blood flow to the affected area of tissue (peripheral perfusion). It works by gently pulling on the thin tissue covering the tibia (periosteum). This tissue plays a key role in encouraging blood flow to the feet and ankles. The XPD system is a new medical device designed to facilitate PD. It consists of both external fixation and implanted components which are surgically fixated to the tibia to apply controlled stress to the periosteum in order to promote blood vessel formation and tissue regeneration. This is a multi-centre, open label, single arm study to evaluate the safety of the XPD System for PD in participants with hard to heal ulcers in the peripheral lower extremities (ankle and below). Chronic ulcers will be graded using the Wound, Ischemia, and foot Infection (WIFi) scale (W)1-2, (I)1-3, (fI)0-1 based on physician judgement. All patients will have a procedure for sharp debridement and installation of the XPD System to perform PD for 3 weeks. The patients will return at 4 weeks for removal of the device and begin an observation period for 16 additional weeks for a total of 20-week follow-up period.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
138670
0
Dr Olofemi Oshin
Query!
Address
138670
0
Royal Perth Hospital. 197 Wellington Street, Perth WA 6000
Query!
Country
138670
0
Australia
Query!
Phone
138670
0
+61 08 9386 9588
Query!
Fax
138670
0
Query!
Email
138670
0
[email protected]
Query!
Contact person for public queries
Name
138671
0
Johnny Chen
Query!
Address
138671
0
BioDynamik Inc. 11 Orchard Rd Suite 107, Lake Forest, CA 92630
Query!
Country
138671
0
United States of America
Query!
Phone
138671
0
+1 949 235 5554
Query!
Fax
138671
0
Query!
Email
138671
0
[email protected]
Query!
Contact person for scientific queries
Name
138672
0
Johnny Chen
Query!
Address
138672
0
BioDynamik Inc. 11 Orchard Rd Suite 107, Lake Forest, CA 92630
Query!
Country
138672
0
United States of America
Query!
Phone
138672
0
+1 949 235 5554
Query!
Fax
138672
0
Query!
Email
138672
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF